Close Menu

NEW YORK – The US Food and Drug Administration expanded the indication for AstraZeneca and Merck's olaparib (Lynparza) as a maintenance treatment for certain metastatic pancreatic cancer patients identified with the help of a companion diagnostic, the two drugmakers announced on Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.